Shire Patent Suit Dismissal Will Delay Generic: Alkem

Law360, New York (December 6, 2011, 5:08 PM EST) -- Alkem Laboratories Ltd. on Tuesday moved to block Shire Canada Inc.'s voluntary dismissal of its Illinois suit accusing the drugmaker of infringing its patents for kidney failure treatment Fosrenol, saying the dismissal would delay Alkem from getting its generic to market.

Alkem said in Illinois federal court that Shire's offer of a covenant not to sue would not qualify under the Hatch-Waxman Act as a triggering event that would allow Alkem to expedite its Fosrenol copy through the U.S. Food and Drug Administration's generics approval process....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.